Peripheral T-cell lymphomas (PTCLs) are a group of highly aggressive malignancies with
generally poor prognoses, and the first-line chemotherapy of PTCL has limited efficacy …

Background: The overall survival of peripheral T-cell lymphoma (PTCL) is dismal. Histone
deacetylase (HDAC) inhibitors have exhibited promising treatment outcomes for PTCL …

Peripheral T-cell lymphomas (PTCLs) are uniquely vulnerable to epigenetic modifiers. We
demonstrated in vitro synergism between histone deacetylase inhibitors and DNA …

Introduction: The peripheral T-cell lymphomas (PTCL) are a rare and heterogeneous group
of non-Hodgkin lymphomas originating from mature T-and NK-cells. They are aggressive …

Histone deacetylase inhibitors (HDACi) are epigenetic modifiers with single-agent activity in
patients with cutaneous and peripheral T-cell lymphoma (CTCL, PTCL). The mechanisms for …

Background: Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of non-Hodgkin
lymphomas associated with poor prognosis and repeated recurrence for most subtypes …

Peripheral T-cell lymphomas (PTCLs) are rare neoplasms constituting a heterogeneous
group of diseases. At present, available chemotherapy regimens that have improved …

Tucidinostat (formerly known as chidamide) is an orally available, novel benzamide class of
histone deacetylase (HDAC) inhibitor that selectively blocks class I and class IIb HDAC. This …

8507 Background: Therapies approved in US for R/R PTCL have overall response rates
(ORR) of 25%-27%. The need for new therapies persists. BELIEF is a pivotal, single-arm …

Objective: To assess the efficacy and safety of the novel histone deacetylase inhibitor,
chidamide, in combination with cyclophosphamide, doxorubicin, vincristine, etoposide, and …